FDA Investigates ByHeart Baby Formula After 13 Infants Hospitalized with Botulism Across 10 States
核心洞察
At least 13 infants across 10 states have been hospitalized with botulism (搜索) after consuming ByHeart Whole Nutrition Infant Formula (搜索) between August and November 2024.
Preliminary tests by California health officials detected bacteria that produces botulism (搜索) toxin in the recalled formula, marking an extremely rare occurrence in powdered infant formula.
ByHeart voluntarily recalled two specific lots of their formula with lot numbers 206VABP/251131P2 and 206VABP/251261P2, both with December 1, 2026 expiration dates.
The U.S. Food and Drug Administration (搜索) has launched a multistate investigation into ByHeart baby formula after at least 13 infants were hospitalized with botulism (搜索) across 10 states between August and November 2024. The affected states include Arizona, California, Illinois, Minnesota, New Jersey, Oregon, Pennsylvania, Rhode Island, Texas, and Washington, with all cases linked to consumption of ByHeart Whole Nutrition Infant Formula (搜索).
Preliminary Testing Reveals Contamination
California Department of Public Health officials conducted preliminary tests on a can of the powdered formula that was fed to an affected infant. The results "suggest the presence" of the type of bacteria that produces the botulism (搜索) toxin confirmed in other cases, though additional testing is needed for confirmation. This finding represents an extremely rare occurrence, as no known outbreaks of infant botulism (搜索) tied to powdered formula have previously been confirmed.
"This would be extremely rare," said Dr. Steven Abrams, a University of Texas nutrition expert, highlighting the unprecedented nature of this outbreak.
Voluntary Recall and Safety Measures
ByHeart agreed to voluntarily recall two specific lots of their Whole Nutrition Infant Formula: lot numbers 206VABP/251131P2 and 206VABP/251261P2, both carrying a use-by date of December 1, 2026. The lot numbers can be found on the bottom of the formula cans. The FDA has advised consumers to note the issue on affected cans and dispose of them immediately.
"The safety and well-being of every infant who uses our formula is our absolute highest priority," stated Mia Funt, Co-Founder and President of ByHeart. "This voluntary recall is out of an abundance of caution and comes from our ongoing commitment to transparency and safety for babies and their parents."
Clinical Presentation and Treatment
The outbreak has affected infants ranging from 2 weeks to 5 months of age. Infant botulism (搜索) symptoms can take weeks to develop and include poor feeding, loss of head control, drooping eyelids, and a flat facial expression. Babies may feel "floppy" and can experience problems swallowing or breathing, potentially progressing to difficulty breathing and possible respiratory arrest.
All 13 hospitalized infants received BabyBIG, the only available treatment for infant botulism (搜索). This IV medication, made from pooled blood plasma of adults immunized against botulism (搜索), is produced exclusively by California's Infant Botulism Treatment and Prevention Program (搜索). The treatment works to shorten hospital stays and decrease illness severity, though infants often require ventilator support due to breathing difficulties.
Broader Investigation Context
The FDA is investigating a total of 83 cases of infant botulism (搜索) reported nationwide since August, including the cases linked to ByHeart formula. Infant botulism typically affects fewer than 200 babies in the U.S. annually and is caused by bacteria that produce toxins in the large intestine. Infants younger than 1 year are particularly vulnerable to exposure from spores present in dust, dirt, water, or contaminated honey.
Market Impact and Supply Concerns
ByHeart, founded in 2016, accounts for an estimated 1% of national formula sales according to the CDC (搜索). The company sells formula through its website and retail stores nationwide. The FDA has indicated that this recall should not create shortage concerns due to the limited market share.
This outbreak differs significantly from the 2021-2022 Abbott Nutrition crisis, where four infants were sickened by cronobacter sakazakii contamination, resulting in two deaths and a massive nationwide formula shortage lasting months.
Regulatory Response and Future Oversight
Health Secretary Robert F. Kennedy Jr. has directed the FDA to review nutrients and other ingredients in infant formula through an initiative dubbed "Operation Stork Speed" - the first comprehensive review of formula ingredients since 1998. This review comes as federal health officials have vowed to overhaul the U.S. food supply system.
ByHeart has faced previous regulatory challenges, including a 2022 recall of five formula batches after cronobacter sakazakii contamination was detected at their packaging plant. In 2023, the FDA issued a warning letter to the company detailing "areas that still require corrective actions."